QCDx

QCDx, Inc. (Farmington, CT) develops RareScope™ light-sheet fluorescence microscopy and RareSoft™ analytics for enrichment-free, ultra-sensitive live-CTC detection and phenotyping actionable therapeutic targets. QCDx highlights live-cell, hours-long visualization assays demonstrating ADC and bispecific MOA, including Trastuzumab trafficking into HER2+ cells; CD19×CD3 accumulation at T-cell/B-cell synapses; and PSMA×CD3–driven T-cell engagement with prostate cancer cells. The platform could support all phases of drug discovery and development.